SCYNEXIS, Inc. (SCYX)
SCYNEXIS, Inc.
1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302-6548
United States
201 884 5485
https://www.scynexis.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 29
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. David Gonzalez Angulo M.D. | CEO, President & Director | 868.03k | N/D | 1965 |
| Mr. Scott Sukenick J.D. | Chief Legal Officer & Corporate Secretary | 623.7k | N/D | 1978 |
| Mr. Ivor Macleod CPA, M.B.A. | Chief Financial Officer | 626.9k | N/D | 1961 |
| Ms. Daniella Gigante | Vice President of Human Resources & Information Technology | N/D | N/D | N/D |
Descripción
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Gestión corporativa
La calificación ISS Governance QuickScore de SCYNEXIS, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
